LY6G6D Recombinant Monoclonal Antibody

Code CSB-RA013246MA2HU
Size US$210
Order now
Image
  • The Binding Activity of Rat Ly6g6d with Anti-LY6G6D Recombinant Antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized Rat Ly6g6d (CSB-YP750592RA) at 5 μg/mL can bind Anti-LY6G6D recombinant antibody. The EC50 is 4.245-5.843 μg/mL.
  • The Binding Activity of Human LY6G6D with Anti-LY6G6D Recombinant Antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized Human LY6G6D (CSB-YP013246HU) at 2 μg/mL can bind Anti-LY6G6D recombinant antibody. The EC50 is 1.840-2.204 ng/mL.
  • The Binding Activity of Mouse Ly6g6d with Anti-LY6G6D Recombinant Antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized Mouse Ly6g6d (CSB-YP4973MO) at 2 μg/mL can bind Anti-LY6G6D recombinant antibody. The EC50 is 1.159-2.305 μg/mL.
  • The Binding Activity of Macaca fascicularis LY6G6D with Anti-LY6G6D Recombinant Antibody
    Activity: Measured by its binding ability in a functional ELISA. Immobilized Macaca fascicularis LY6G6D (CSB-YP4607MOV) at 2 μg/mL can bind Anti-LY6G6D recombinant antibody. The EC50 is 16.16-25.29 ng/mL.
  • Untransfected HEK293T cells (green line) and transfected Human LY6G6D HEK293T stable cells (red line) were stained with anti-LY6G6D antibody (2µg/1*106cells), washed and then followed by FITC-conjugated anti-Mouse IgG Fc antibody and analyzed with flow cytometry.
  • Untransfected CT26 cells surface (green line) and transfected Human LY6G6D CT26 stable cells surface (red line) were stained with anti-LY6G6D antibody (2µg/1*106cells), washed and then followed by FITC-conjugated anti-Mouse IgG Fc antibody and analyzed with flow cytometry.
Have Questions? Leave a Message or Start an on-line Chat

Product Details

Uniprot No.
Target Names
Alternative Names
Lymphocyte antigen 6 complex locus protein G6d; Protein Ly6-D; Megakaryocyte-enhanced gene transcript 1 protein; LY6G6D; C6orf23; G6D; MEGT1; NG25
Species Reactivity
Human, Mouse, Rat, Macaca fascicularis
Immunogen
Recombinant Human LY6G6D protein
Immunogen Species
Homo sapiens (Human)
Conjugate
Non-conjugated
Clonality
Monoclonal
Isotype
mIgG2b
Clone No.
2D6
Purification Method
Affinity-chromatography
Concentration
It differs from different batches. Please contact us to confirm it.
Buffer
Preservative: 0.03% Proclin 300
Constituents: 50% Glycerol, 0.01M PBS, PH 7.4
Form
Liquid
Tested Applications
ELISA, FC
Recommended Dilution
Application Recommended Dilution
FC 1:50-1:200
Troubleshooting and FAQs
Storage
Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.
Lead Time
Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Usage
For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Customer Reviews and Q&A

 Customer Reviews

There are currently no reviews for this product.

Submit a Review here

Target Background

Gene References into Functions
  1. Frequencies of the DRB1, DQA1, DQB1 and TNFA alleles in immigrant population of West Siberia PMID: 19807019
Subcellular Location
Cell membrane; Lipid-anchor, GPI-anchor. Cell projection, filopodium.
Tissue Specificity
Expressed in the adult lung, and in fetal liver, lung, kidney, brain and spleen.
Database Links

HGNC: 13935

OMIM: 606038

KEGG: hsa:58530

STRING: 9606.ENSP00000364985

UniGene: Hs.591792

icon of phone
Call us
301-363-4651 (Available 9 a.m. to 5 p.m. CST from Monday to Friday)
icon of address
Address
7505 Fannin St., Ste 610, Room 7 (CUBIO Innovation Center), Houston, TX 77054, USA
icon of social media
Join us with

Subscribe newsletter

Leave a message

* To protect against spam, please pass the CAPTCHA test below.
CAPTCHA verification
© 2007-2025 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1
Place an order now

I. Product details

*
*
*
*

II. Contact details

*
*

III. Ship To

*
*
*
*
*
*
*

IV. Bill To

*
*
*
*
*
*
*
*